Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Melanoma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Thoracic Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Newly Diagnosed Glioblastoma 1Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Lymphoma, Large B-Cell, Diffuse 1Locally Advanced or Metastatic Solid Tumors 1Glioma 1Carcinoma, Merkel Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

pembrolizumab 4toripalimab 1efineptakin alfa 1MK 2206 1Injections 1Cetuximab 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Locally Advanced or Metastatic Solid Tumors × efineptakin alfa × Clear all
NCT03478995 2020-05-11

Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors

Genexine, Inc.

Phase 1 Completed
35 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡